Capecitabine Market Analysis by Advanced Technology, Trends, Forecasts to 2030
Capecitabine Market Overview: The Capecitabine Market was valued at USD 1,020.00 Million in 2022.and is estimated to reach over USD 1,558.74 Million by 2030 and grow at a CAGR of 5.5% during the forecast period. Capecitabine, a prodrug of fluorouracil, has become a mainstay in cancer treatment, particularly for colorectal and breast cancers. Its unique oral administration and manageable side effects compared to other chemotherapies have fueled its popularity. Let's delve deeper into the capecitabine market, exploring its key aspects: This growth is driven by several factors, including: Rising cancer burden worldwide, particularly colorectal and breast cancers. Increasing awareness and early diagnosis of these cancers. Proven efficacy of capecitabine in various treatment regimens. Patent expiry of Xeloda, the leading brand of capecitabine, opening doors for generics. Capecitabine Market Drivers: Rising cancer incidence: The increasing number of cancer diagnoses, e...